Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017457 | 0.87 | TP53 (0.38) | MAPTSIRT2 | |
| SCHEMBL16017463 | 0.87 | TP53 (0.38) | MAPTSIRT2 | |
| SCHEMBL16019944 | 0.83 | ACE (0.48) | PPARGALDH1A1ACEPPARA | |
| SCHEMBL27405017 | 0.76 | POLB (0.36) | ALDH1A1MAPTCNR2 | |
| SCHEMBL7969401 | 0.76 | AKR1B1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL14454002 | 0.75 | SIRT2 (0.57) | SIRT2 | |
| SCHEMBL23532128 | 0.73 | CYP11B1 (0.36) | ALDH1A1SIRT2 | |
| SCHEMBL689517 | 0.73 | CYP11B1 (0.36) | — | |
| SCHEMBL688676 | 0.73 | KEAP1 (0.40) | ALDH1A1MAPT | |
| SCHEMBL16017454 | 0.72 | MAPT (0.34) | ALDH1A1MAPTSIRT2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | VIROBAY, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | CTSF, CTSZ, CTSV | NPSR1 2382/4885PPARG 3930/4885ALDH1A1 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.